查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1800137

全球基因检测市场：2025年至2030年预测

Global Genetic Testing Market - Forecasts fom 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

基因检测市场规模预计将从 2025 年的 149.04 亿美元成长至 2030 年的 248.89 亿美元，复合年增长率为 10.80%。

由于人口老化、遗传病患病率上升以及人们对早期疾病检测意识的不断增强等因素，基因检测市场正经历强劲增长。技术进步和预防性医疗保健应用的不断扩展进一步推动了市场的发展。研发投入正在推动技术创新，并将基因检测定位为医疗诊断的关键工具。然而，高成本可能会抑製成长。本摘要专为行业专业人士量身定制，重点介绍了截至2025年的关键驱动因素、区域趋势和竞争考察。

市场成长动力

遗传疾病盛行率的上升以及对早期检测和个人化医疗日益增长的重视，推动了基因检测市场的发展。全球人口老化加剧了对遗传疾病检测的需求。包括次世代定序和检测设备改进在内的技术进步，正在提高检测的准确性和可及性，促进其在医疗保健和科研领域的应用。研发投入的增加正在加速技术创新，新的检测方法也正在扩大其在疾病预防和管理的应用。然而，高昂的检测成本、不一致的报销政策以及熟练专业人员的短缺构成了挑战，尤其是在法律规范仍在发展的新兴市场。

地理视角

北美在基因检测市场占据主导地位，这得益于先进的技术基础设施、高发生率的遗传疾病以及强劲的研发投入。该地区完善的医疗保健体系和基因检测在诊断领域的广泛应用，确保了其市场领先地位。然而，预计亚太地区将经历最快的成长，这得益于患者人数的增加、购买力的提升以及中国和印度等国家政府对医疗创新的资助。儘管有这样的潜力，但高昂的成本和监管的不确定性可能会限制亚太地区和其他新兴经济体的成长。

调查方法

我们的市场分析采用严谨的方法，将产业报告中的二手资料与相关人员的一手资料结合并检验。市场规模和预测采用自上而下和自下而上的方法计算，以确保准确性。报告按应用、技术和地区细分市场，以提供全面的趋势和机会视角。产业价值链分析和波特五力模型进一步揭示了市场动态、监管影响和竞争压力。

竞争考察

基因检测市场的主要企业包括罗氏公司 (F. Hoffmann-La Roche Ltd.)、23&Me, Inc.、Precipio, Inc.、AutoGenomics、雅培实验室 (Abbott Laboratories) 和 Luminex Corporation。这些公司透过持续研发、产品创新和策略联盟来推动市场成长。他们专注于开发先进的检测平台，以提高诊断准确性并推动市场发展。由于需要大量的研发成本和专业知识，进入门槛较高，从而塑造了竞争格局，增强了现有企业的市场影响力。

受人口老化、遗传病患疾病上升以及技术进步的推动，基因检测市场可望迎来显着成长。北美市场目前处于领先地位，而亚太地区则因医疗保健投资的增加而逐渐成为高成长地区。儘管高成本和监管缺口等挑战依然存在，但持续的研发和技术创新可望支撑市场持续扩张。领先的公司不断透过先进的解决方案巩固其市场地位，将基因检测定位为现代医疗保健的基石。

本报告的主要优点

  • 深刻分析：获得涵盖主要和新兴地区的深入市场洞察，重点关注客户群、政府政策和社会经济因素、消费者偏好、垂直行业和其他细分市场。
  • 竞争格局：了解主要企业采用的策略策略，并了解正确策略的市场渗透潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力进行策略决策并在动态环境中开闢新的业务流和收益。
  • 适合广泛的使用者：对于新兴企业、研究机构、顾问、中小企业和大型企业来说都是有益且具有成本效益的。

它有什么用途？

产业和市场考量、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2020 年至 2024 年的历史数据和 2025 年至 2030 年的预测数据
  • 成长机会、挑战、供应链前景、法律规范与趋势分析
  • 竞争定位、策略和市场占有率分析
  • 收益成长和预测细分市场和区域分析（包括国家）
  • 公司概况（尤其是趋势）、财务资讯和关键发展

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 调查范围
  • 市场区隔

第三章 经营状况

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策法规
  • 策略建议

第四章 技术展望

第五章全球基因检测市场类型

  • 介绍
  • 产前检查
  • 新生儿筛检
  • 诊断测试
  • 职业测试
  • 预测性和症状前检测

第六章 全球基因检测市场（按疾病）

  • 介绍
  • 癌症
  • 囊肿纤维化
  • 镰状细胞性贫血
  • Duchenne氏肌肉失养症
  • 阿兹海默症
  • 地中海型贫血
  • 亨丁顿舞蹈症
  • 其他的

7. 全球基因检测市场（按技术）

  • 介绍
  • 细胞遗传学检测
  • 生物化学检验
  • 分子检测
  • 其他的

第 8 章：全球基因检测市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 其他的

第九章竞争格局及分析

  • 主要企业和策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章：公司简介

  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Precipio, Inc.
  • Ariosa Diagnostics, Inc.
  • Biocartis SA
  • Danaher Corporation
  • 23&Me, Inc.
  • DiaSorin
  • Labcorp
  • AutoGenomics
  • Illumina, Inc
  • Thermo Fisher Scientific

第十一章 附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益
  • 调查方法
  • 简称
简介目录
Product Code: KSI061610991

The Global Genetic Testing Market is expected to grow from USD 14.904 billion in 2025 to USD 24.889 billion in 2030, at a CAGR of 10.80%.

The global genetic testing market is experiencing robust growth, driven by an aging population, increasing prevalence of genetic and hereditary diseases, and growing awareness of early disease detection. Technological advancements and expanding applications in preventive healthcare further propel the market. Investments in research and development (R&D) are fostering innovation, positioning genetic testing as a critical tool in medical diagnostics. However, challenges such as high costs, unclear reimbursement structures, lack of skilled personnel, and regulatory gaps may restrain growth. This summary, tailored for industry experts, highlights key drivers, geographical trends, and competitive insights as of 2025.

Market Growth Drivers

The genetic testing market is fueled by the rising incidence of genetic disorders and the growing emphasis on early detection and personalized medicine. An aging global population increases demand for tests to identify hereditary conditions. Technological advancements, including next-generation sequencing and improved testing equipment, enhance accuracy and accessibility, driving adoption across medical and research sectors. Increased R&D investments are accelerating innovation, with new testing methodologies expanding applications in disease prevention and management. However, high testing costs, inconsistent reimbursement policies, and a shortage of skilled professionals pose challenges, particularly in emerging markets where regulatory frameworks are still evolving.

Geographical Outlook

North America dominates the genetic testing market, supported by advanced technological infrastructure, a high prevalence of genetic diseases, and robust R&D investments. The region's well-established healthcare systems and widespread adoption of genetic testing for diagnostics ensure its market leadership. The Asia-Pacific (APAC) region, however, is projected to experience the fastest growth, driven by a rising patient pool, increasing purchasing power, and government funding for healthcare innovation in countries like China and India. Despite this potential, high costs and regulatory uncertainties may limit growth in APAC and other emerging economies.

Research Methodology

The market analysis employs a rigorous methodology, combining secondary data from industry reports and primary inputs from stakeholders for validation. Market size and forecasts are calculated using both top-down and bottom-up approaches, ensuring accuracy. The report segments the market by application, technology, and geography, providing a comprehensive view of trends and opportunities. Industry value chain analysis and Porter's Five Forces model further elucidate market dynamics, regulatory influences, and competitive pressures.

Competitive Insights

Key players in the genetic testing market include F. Hoffmann-La Roche Ltd, 23&Me, Inc., Precipio, Inc., AutoGenomics, Abbott Laboratories, and Luminex Corporation. These companies drive market growth through continuous R&D, product innovation, and strategic partnerships. Their focus on developing advanced testing platforms enhances diagnostic precision and expands market reach. The competitive landscape is shaped by high entry barriers due to significant R&D costs and the need for specialized expertise, consolidating market dominance among established players.

The genetic testing market is poised for significant growth, driven by an aging population, rising genetic disease prevalence, and technological advancements. North America leads, while APAC emerges as a high-growth region due to increasing healthcare investments. Challenges like high costs and regulatory gaps persist, but ongoing R&D and innovation are expected to sustain market expansion. Major players continue to strengthen their positions through advanced solutions, positioning genetic testing as a cornerstone of modern healthcare.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2020 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation

The genetic testing market has been segmented by product type, diseases, technology, and geography:

By Type

  • Prenatal Testing
  • New Born Screening
  • Diagnostic Testing
  • Carrier Testing
  • Predictive & Pre-symptomatic Testing

By Diseases

  • Cancer
  • Cystic Fibrosis
  • Sickle Cell Anemia
  • Duchenne's Muscular Dystrophy
  • Alzheimer's Diseases
  • Thalassemia
  • Huntington's Disease
  • Others

By Technology

  • Cyto-genetics Testing
  • Biochemical Testing
  • Molecular Testing
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL GENETIC TESTING MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Prenatal Testing
  • 5.3. New Born Screening
  • 5.4. Diagnostic Testing
  • 5.5. Carrier Testing
  • 5.6. Predictive & Pre-symptomatic Testing

6. GLOBAL GENETIC TESTING MARKET BY DISEASE

  • 6.1. Introduction
  • 6.2. Cancer
  • 6.3. Cystic Fibrosis
  • 6.4. Sickle Cell Anemia
  • 6.5. Duchenne's Muscular Dystrophy
  • 6.6. Alzheimer's Disease
  • 6.7. Thalassemia
  • 6.8. Huntington's Disease
  • 6.9. Others

7. GLOBAL GENETIC TESTING MARKET BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Cyto-genetics Testing
  • 7.3. Biochemical Testing
  • 7.4. Molecular Testing
  • 7.5. Others

8. GLOBAL GENETIC TESTING MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Others
  • 8.5. Middle East & Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. Australia
    • 8.6.5. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. F. Hoffmann-La Roche Ltd
  • 10.2. Abbott Laboratories
  • 10.3. Precipio, Inc.
  • 10.4. Ariosa Diagnostics, Inc.
  • 10.5. Biocartis SA
  • 10.6. Danaher Corporation
  • 10.7. 23&Me, Inc.
  • 10.8. DiaSorin
  • 10.9. Labcorp
  • 10.10. AutoGenomics
  • 10.11. Illumina, Inc
  • 10.12. Thermo Fisher Scientific

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations